Apolipoprotein B-48 and late graft failure in kidney transplant recipients.

Apolipoprotein B-48 dyslipidemia kidney transplantation late graft failure prospective longitudinal cohort study

Journal

Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321

Informations de publication

Date de publication:
Oct 2024
Historique:
received: 21 03 2024
medline: 21 10 2024
pubmed: 21 10 2024
entrez: 21 10 2024
Statut: epublish

Résumé

Transplant vasculopathy resembles atherosclerotic plaque formation and is a major contributor to late graft failure in kidney transplant recipients (KTR). Remnant lipoproteins and associated triglycerides are causal risk factors for atherosclerotic plaques and have been implicated in late kidney graft failure. However, whether remnants derived from liver (containing apolipoprotein [apo] B100) or intestine (containing apoB48) are clinically more important is unclear. The current study investigated the association between baseline fasting apoB48 levels and late kidney graft failure. 481 KTR with a functioning graft for at least 1 year were included in this retrospective, observational longitudinal single center cohort study. The primary endpoint was death-censored late graft failure, defined as need for initiation of dialysis or re-transplantation. ApoB48 was measured by enzyme-linked immunosorbent assay. During a median follow-up of 9.5 years, 61 KTR developed graft failure (12.7%). At baseline, KTR with higher apoB48 levels had lower eGFR ( ApoB48 is strongly associated with late graft failure, independent of potential confounders. Since apoB48-containing lipoproteins originate from the intestine, this study provides a rationale for considering pharmacological interventions targeting lipid absorption to improve graft outcome.

Identifiants

pubmed: 39430793
doi: 10.1093/ckj/sfae289
pii: sfae289
pmc: PMC11487158
doi:

Types de publication

Journal Article

Langues

eng

Pagination

sfae289

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the ERA.

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Auteurs

Tamas Szili-Torok (T)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Martin H de Borst (MH)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Alexandra Soteriou (A)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Laura Post (L)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Stephan J L Bakker (SJL)

Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.

Uwe J F Tietge (UJF)

Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Clinical Chemistry, Karolinska University Laboratory, Karolinska University Hospital, Stockholm, Sweden.

Classifications MeSH